– Onegevity Health announced it has acquired global licensing rights to Mount Sinai’s Lab100 clinic that uses precision diagnostics to empower patients and help scientists advance our understanding of human health.
– Clinic and research lab offers patients access to comprehensive health assessment, expands clinical understanding of disease prevention and provides a wealth of health outcomes data.
Today, NYC-based health tech company, Onegevity Health, announced it acquired the global licensing rights to Mount Sinai’s Lab100, a clinic and research lab that uses precision diagnostics to empower patients and help scientists advance our understanding of human health. Lab100 opened to the public last fall and is currently only available at Mount Sinai Hospital, but will soon be available at other medical systems nationwide. Financial details of the acquisition were not disclosed.
Lab100, currently available at The Mount Sinai Hospital’s Upper East Side location in New York City, opened to the public in fall 2018 and has seen more than 400 patients to date. The lab is designed to support the transition in focus from sick-care to well-care – away from reacting to disease towards a more predictive model that empowers patients with personalized information needed to be proactive about maintaining health. Lab100 will continue to be available to patients at Mount Sinai.
Lab100 for Patients, Clinicians, Researchers, Innovators
For patients and clinicians, Lab100 offers a highly personalized health experience focused towards a more predictive model that empowers patients with personalized information needed to be proactive about maintaining health. For researchers and innovators, the health assessments translate to a wealth of data that could lead to breakthroughs in science and innovative new healthcare practices.
Why It Matters
“Lab100 has created an exciting opportunity for patients, providers, researchers and innovators to come together to develop the next generation of healthcare,” says Paul Jacobson, chief executive officer of Onegevity and Thorne, a health and technology company that provides supplements and at-home biomarker tests. “Onegevity, in conjunction with other partners, plans to bring Lab100 to more people and communities in the coming months and years. We are looking forward to partnering with innovators and improving our healthcare system by preventing disease to produce lower costs and better outcomes for all.”